How much does it cost. >> It is a six-f figureure program. >> Like 100,000 or 500,000 or 800,000 cuz there's a big range.>> Much closer to 100,000 than 500,000. >> That's a lot of money. I mean, what do you get for that. You don't get I mean, you don't live forever.>> Nope. You're getting access to me, a team of a couple other physicians, a strength and conditioning team, a nutrition team, and what you're really getting is a path to help you achieve your goal of living longer and living Better. ...

Core Insights - Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic plan [1][2] - The company will redirect its focus and resources towards advancing its Klotho anti-aging protein research pipeline and developing treatments that promise the greatest value for patients and shareholders [2] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company dedicated to developing innovative, disease-modifying cell and gene therapies utilizing a protein derived from the patented "anti-aging" human Klotho gene [4] - The company aims to transform the treatment of neurodegenerative and age-related disorders, including ALS, Alzheimer's disease, and Parkinson's disease, through its proprietary cell and gene therapy programs [4] Market Context - The longevity medicine market is one of the fastest-growing global sectors, driven by an aging population projected to reach 2.1 billion by 2050 [3] - Healthcare costs are currently at 10% of global GDP and are expected to exceed $47 trillion by 2030, highlighting the significant opportunity in the longevity sector [3]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue declined by 3.6%, with EBITDA and net profit decreasing by 1.6% and 3.8% respectively [27][28][33] - The EBITDA margin for Q2 was 41.6%, while the net profit margin was 30.4% [27][33] - For the first half of 2025, total revenue was down 4.6%, with a 5.3% decline in hospital operation revenue [30][33] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [27][30] - The outpatient service revenue contribution increased to 51% in the first half of 2025, up from 49% in the same period last year [31] - The government third-party contribution dropped to 14% from 18% in the first half of last year due to lower Middle East revenue [31] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [6][7] - The company experienced a decline in revenue from the Indo-China segment, particularly from Cambodia, which was offset by growth in Myanmar and Bangladesh [29][30] - The Chinese market saw a significant reduction in patient arrivals, down by over 30% to 40% year over year due to safety concerns [65][66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services and enhancing patient experience through new facilities and advanced technologies [88][92] - There is an emphasis on strengthening relationships with key stakeholders and third-party payers to drive growth [84] - The company aims to improve its market position by addressing governance issues and enhancing service quality for Kuwaiti patients [42][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [18][26] - The company is cautiously optimistic about the return of Kuwaiti patients and the resolution of past payment issues [46][56] - Management highlighted the importance of addressing safety concerns to regain Chinese patient trust and increase medical tourism [66][70] Other Important Information - The company achieved recognition as one of the best specialized hospitals in Thailand across multiple specialties [77][78] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [80] - The company is actively investing excess cash into financial assets to capture higher interest income [34][35] Q&A Session Summary Question: What are the expectations for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future collaborations and patient flow [46][56] Question: How is the company addressing the decline in Chinese patient arrivals? - The company is expanding its presence in China and engaging in targeted outreach to rebuild trust and increase referrals [66][70] Question: What are the key initiatives for cancer care expansion? - The company is focusing on comprehensive cancer care, integrating advanced technologies, and enhancing patient experience through new facilities [88][92]